BTIG analyst David Larsen raised the firm’s price target on BrightSpring Health (BTSG) to $30 from $25 and keeps a Buy rating on the shares as part of a broader research note in summary of presentations at the recent Boston Digital Health Summit. The firm is citing the fairly high drug price inflation rates, especially amongst specialty and oncology medications, as well as good volumes, especially in the post-acute environment in boosting its price target on BrightSpring.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health Services, Inc.: Strong Growth Prospects and Strategic Positioning Drive Buy Rating
- BrightSpring Health price target raised to $27 from $25 at Wells Fargo
- BrightSpring Health Services, Inc.: Strong Financial Performance and Strategic Growth Drive Buy Rating
- BrightSpring Health 11.23M share Block Trade priced at $20.30
- BrightSpring Health Services, Inc. Earns Buy Rating Amid Strong Financial Performance and Promising Outlook